<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458513477817</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458513477817</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Corrigendum</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum</article-title>
</title-group>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>382</fpage>
<lpage>382</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<related-article ext-link-type="doi" id="related-article1-1352458513477817" related-article-type="corrected-article" xlink:href="10.1177/1352458512459019"/>
<abstract>
<p>The authors would like to apologise for errors made in <italic>ECTRIMS, Supplement 4, October 2012, 28<sup>th</sup> Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10-13 October 2012, Lyon, France</italic>.</p>
</abstract>
</article-meta>
</front>
<body>
<p>In the abstract P273; <italic>‘Sustained improvement in urinary incontinence and quality of life with onabotulinumtoxinA regardless of baseline EDSS score in MS patients with neurogenic detrusor overactivity’</italic>, by Mark Tullman et al, there were analytical errors that were corrected for the poster presented at the meeting. The correct information for the abstract should be as follows:</p>
<p>[1]</p>
<p>Reductions in UI episodes by baseline EDSS were: −21.9, −19.7, and −26.8 in MS patients with EDSS ≤4 (cycles 1, 2, and 3, respectively), and −24.3, −25.0, and −25.0 in MS patients with EDSS &gt;4. Increase in IQOL from baseline was 30.3 at week 6 in cycle 1. Increases in IQOL from baseline by EDSS were 37.8, 39.1, and 38.9 in MS patients with EDSS ≤4 (cycles 1, 2, and 3, respectively), and 26.5, 36.4, and 33.0 in MS patients with EDSS &gt;4.</p>
<p>[1] Tullman M, Denys P, Jenkins B, Joshi AJ, Zhou J, Yushmanova I, et al. The MS Center for Innovations in Care (St. Louis, US); Hospital Raymond Poincaré (Garches, FR); Allergan (Irvine, US); National Hospital for Neurology &amp; Neurosurgery (London, UK). [Abstract] presented at <italic>ECTRIMS</italic>, Lyon, France; October 2012.</p>
</body>
</article>